CD8A and Patent ductus arteriosus: As CD8+ CD137+ T cells were very rare on pre-treatment biopsy specimens9, reporting the fold change between pre-treatment baselines and post-neoadjuvant immunotherapy samples would not be meaningful; therefore, this study only reported the density of CD8+ CD137+ T cells in the post-neoadjuvant immunotherapy PDA resected tumors.